MCRPC Gleason 10 T4 M1 N1 with Neuroendocrine prostate cancer. Currently on enzalutamide and relugolix. What...

I appreciate you sharing your diagnosis. This is a complex and serious situation, and I want to help you understand your options while being clear about what I can and cannot do.

What I'm Seeing in Your Case

You have metastatic castration-resistant prostate cancer (mCRPC) with several important features:

• Gleason 10 (highest grade - most aggressive)
• T4 N1 M1 staging (locally advanced, lymph node involvement, distant spread)
• Neuroendocrine differentiation (a particularly aggressive variant)
• Currently on enzalutamide (an androgen receptor inhibitor) and relugolix (an LHRH antagonist)

This combination suggests your cancer has progressed despite hormone therapy, which is why you're on these medications.

The Challenge with Clinical Trials

I cannot determine your specific eligibility for clinical trials because trial enrollment depends on many factors beyond your diagnosis:

• Specific sites of metastasis and extent of disease
• Your organ function (liver, kidney, heart)
• Prior treatments and how you responded
• Performance status (how well you're functioning)
• Specific genetic/molecular testing results (MSI status, TMB, other biomarkers)
• Trial-specific inclusion/exclusion criteria that change frequently

How to Find Trials You're Actually Eligible For

1. Talk to your oncologist FIRST — They have:

• Your complete medical history and imaging
• Access to real-time trial databases
• Knowledge of which trials are actively enrolling at your center
• Ability to review your molecular testing results

2. Search actively yourself:

• ClinicalTrials.gov (NIH) — Filter by "prostate cancer," "mCRPC," "neuroendocrine," your location
• Cancer Commons (cancercommons.org) — Helps match patients to trials based on tumor characteristics
• NCCN Guidelines recommend discussing clinical trial options as part of standard care for mCRPC

3. Ask your team these specific questions:

• "Are there any active trials at our center for mCRPC with neuroendocrine features?"
• "What is my tumor's molecular profile (MSI, TMB, PD-L1 status)?" — This opens doors to immunotherapy trials
• "Am I a candidate for trials combining hormone therapy with chemotherapy, immunotherapy, or targeted agents?"
• "Are there trials specifically for treatment-resistant disease?"

Treatment Landscape for Your Situation

According to NCCN Guidelines for Advanced-Stage Prostate Cancer, patients with mCRPC who progress on initial hormone therapy typically have options including:

• Chemotherapy (docetaxel, cabazitaxel)
• Additional hormone agents
• Immunotherapy (for specific biomarker profiles)
• Combination approaches
• Clinical trials testing novel agents

Neuroendocrine prostate cancer is particularly important because it may respond differently to standard therapies and may benefit from different treatment approaches — this is exactly why clinical trials matter for your case.

What You Should Do Now

1. Request molecular testing results if you haven't already — Ask specifically about:

   • MSI (microsatellite instability)
   • TMB (tumor mutational burden)
   • PD-L1 expression
   • BRCA mutations
   • Other genomic findings

2. Ask your oncologist about trial eligibility at your next appointment — Bring a list of questions

3. Search ClinicalTrials.gov yourself while waiting for your appointment — Look for:

   • "mCRPC" + "neuroendocrine"
   • "castration-resistant prostate cancer" + "immunotherapy"
   • Trials at centers near you

4. Consider a second opinion from a prostate cancer specialist if you're at a smaller center — Major cancer centers often have more trial options

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your oncologist is the right person to determine your specific trial eligibility based on your complete clinical picture.